Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements to investors while concealing material adverse facts regarding the company's capital allocation priorities, particularly concerning its dividend strategy [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Organon securities between November 3, 2022, and April 30, 2025, with a deadline of July 22, 2025, for investors to apply as lead plaintiffs [2]. - The complaint alleges that the defendants made overwhelmingly positive statements while hiding the true state of Organon's priorities, especially regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. Group 2: Stock Price Impact - Following the announcement of the lawsuit and the revelations regarding the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from October 31, 2024, to April 30, 2025 [3]. - Allegations include that Organon provided overly positive statements while concealing material adverse facts about its capital allocation priorities, particularly regarding a debt reduction strategy following the acquisition of Dermavant [3]. Impact on Stock Price - Following the announcement of the dividend reduction, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially become lead plaintiffs and receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to false or misleading statements by companies [5].

Core Viewpoint - Investors in the Medical Services sector should consider Organon (OGN) and Medpace (MEDP) as potential undervalued stocks, with OGN appearing to be the superior option based on valuation metrics and earnings estimate revisions [1][7]. Valuation Metrics - OGN has a forward P/E ratio of 2.47, significantly lower than MEDP's forward P/E of 24.59, indicating that OGN may be undervalued relative to MEDP [5]. - The PEG ratio for OGN is 0.94, while MEDP's PEG ratio is 5.64, suggesting that OGN's expected earnings growth is more favorable compared to its price [5]. - OGN's P/B ratio is 4.54, compared to MEDP's P/B of 15.1, further highlighting OGN's more attractive valuation [6]. Analyst Outlook - OGN currently holds a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while MEDP has a Zacks Rank of 3 (Hold), suggesting a less favorable outlook [3]. - The stronger estimate revision activity for OGN, combined with its attractive valuation metrics, positions it as a more appealing choice for value investors [7].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentations regarding its capital allocation priorities and risks associated with its product Nexplanon during the class period from November 3, 2022, to April 30, 2025 [1][3][4] Company Overview - Organon & Co. is a healthcare company based in Jersey City, NJ, focusing on women's health [2] - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2] Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3] - It is alleged that after the acquisition, Organon shifted its capital allocation focus towards reducing debt rather than maintaining dividends [3] - The lawsuit also states that Organon failed to disclose the heightened risk of loss of exclusivity and price erosion related to its product Nexplanon [4]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon misrepresented the risks associated with its product Nexplanon, suggesting that the company would achieve $1 billion in sales by the end of fiscal year 2025, which is now deemed unlikely [4]. - It is alleged that Organon would not maintain the required $1 billion in free cash flow to sustain its dividend, nor would it maintain a debt leverage ratio of 4.0x, potentially affecting its corporate debt ratings [4]. - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, which led to a stock price drop of over 27% [5]. Legal Process - Investors who purchased Organon securities during the Class Period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [7].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, specifically titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from November 3, 2022, to April 30, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Organon made false or misleading statements regarding its product Nexplanon, including an overstated long-term sales growth projection that would not reach $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve the required $1 billion in free cash flow to sustain its dividend, nor maintain its corporate debt ratings [4].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements to investors while concealing material adverse facts regarding the company's capital allocation priorities, particularly concerning its dividend strategy [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Organon securities between November 3, 2022, and April 30, 2025, with a deadline of July 22, 2025, for investors to apply as lead plaintiffs [2]. - The lawsuit claims that the defendants made overwhelmingly positive statements while hiding the true state of Organon's priorities, especially regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. Group 2: Stock Price Impact - Following the announcement of the lawsuit and the related disclosures, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [5]. Group 3: Investor Communication - Investors who suffered losses or have questions regarding their rights related to the lawsuit are encouraged to contact the law firm Bragar Eagel & Squire for more information [6].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Allegations - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not reach $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve a $1 billion milestone payment from Merck & Co. related to Nexplanon sales, nor maintain the required $1 billion in free cash flow to sustain its dividend [4]. - The lawsuit further asserts that Organon might not maintain its corporate debt ratings and leverage levels, which could impact its financial stability [4]. Financial Impact - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, from $1.16 per share annually to $0.08 per share annually, which led to a stock price drop of over 27% [5].